Sutro Biopharma, Inc.
STRO
Price:
$3.84
Market Cap:
$314.74M
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with M...[Read more]
Industry
Biotechnology
IPO Date
2018-09-27
Stock Exchange
NASDAQ
Ticker
STRO
The ROE as of September 2024 (TTM) for Sutro Biopharma, Inc. (STRO) is -97.19%
According to Sutro Biopharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -97.19%. This represents a change of 240.87% compared to the average of -28.51% of the last 4 quarters.
Sutro Biopharma, Inc. (STRO) Historical ROE (quarterly & annually)
How has STRO ROE performed in the past?
The mean historical ROE of Sutro Biopharma, Inc. over the last ten years is -30.98%. The current -97.19% ROE has changed 213.67% with respect to the historical average. Over the past ten years (40 quarters), STRO's ROE was at its highest in in the March 2018 quarter at 251.59%. The ROE was at its lowest in in the March 2024 quarter at -59.39%.
Average
-30.98%
Median
-34.94%
Minimum
-71.36%
Maximum
18.06%
Sutro Biopharma, Inc. (STRO) ROE by Quarter and Year
Discovering the peaks and valleys of Sutro Biopharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 294.63%
Maximum Annual ROE = 18.06%
Minimum Annual Increase = -1064.67%
Minimum Annual ROE = -71.36%
| Year | ROE | Change |
|---|---|---|
| 2023 | -71.36% | 29.94% |
| 2022 | -54.92% | 27.64% |
| 2021 | -43.03% | 294.63% |
| 2020 | -10.90% | -80.87% |
| 2019 | -57.00% | 112.31% |
| 2018 | -26.85% | -248.65% |
| 2017 | 18.06% | -1064.67% |
Sutro Biopharma, Inc. (STRO) Average ROE
How has STRO ROE performed in the past?
The current ROE of Sutro Biopharma, Inc. (STRO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-56.44%
5-year avg
-47.44%
10-year avg
-30.98%
Sutro Biopharma, Inc. (STRO) ROE vs. Peers
How is STRO’s ROE compared to its peers?
Sutro Biopharma, Inc.’s ROE is greater than Vaxcyte, Inc. (-30.07%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Merus N.V. (-36.33%), greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%), greater than NewAmsterdam Pharma Company N.V. (-81.09%), greater than Centessa Pharmaceuticals plc (-63.22%), less than Opthea Limited (360.05%), greater than HilleVax, Inc. (-62.01%), less than Eliem Therapeutics, Inc. (0%), greater than Genenta Science S.p.A. (-47.03%), greater than Pardes Biosciences, Inc. (-50.79%), greater than Aerovate Therapeutics, Inc. (-54.84%), greater than Mineralys Therapeutics, Inc. (-83.65%), greater than Replimune Group, Inc. (-42.61%), greater than null (-52.15%),
| Company | ROE | Market cap |
|---|---|---|
| -30.07% | $13.88B | |
| -37.84% | $425.59M | |
| -57.42% | $1.53B | |
| -36.33% | $3.42B | |
| -20.53% | $3.13B | |
| -255.67% | $1.17B | |
| -86.28% | $325.08M | |
| -44.73% | $2.07B | |
| -100.91% | $3.02M | |
| -81.09% | $1.41B | |
| -63.22% | $1.85B | |
| 360.05% | $511.67M | |
| -62.01% | $89.61M | |
| 0% | $551.23M | |
| -47.03% | $65.58M | |
| -50.79% | $135.19M | |
| -54.84% | $55.43M | |
| -83.65% | $575.34M | |
| -42.61% | $716.35M | |
| -52.15% | $0 |
Build a custom stock screener for Sutro Biopharma, Inc. (STRO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sutro Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Sutro Biopharma, Inc. (STRO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Sutro Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Sutro Biopharma, Inc.'s ROE?
How is the ROE calculated for Sutro Biopharma, Inc. (STRO)?
What is the highest ROE for Sutro Biopharma, Inc. (STRO)?
What is the 3-year average ROE for Sutro Biopharma, Inc. (STRO)?
What is the 5-year average ROE for Sutro Biopharma, Inc. (STRO)?
How does the current ROE for Sutro Biopharma, Inc. (STRO) compare to its historical average?